Nurix Therapeutics, Inc.NRIXEarnings & Financial Report
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel targeted protein degradation therapies for cancer, immune disorders and other serious unmet medical needs. Its core pipeline leverages proprietary E3 ubiquitin ligase modulation technology, with operations primarily based in the United States and collaborative partnerships with global pharmaceutical firms.
NRIX Q4 FY2025 Key Financial Metrics
Revenue
$13.6M
Gross Profit
N/A
Operating Profit
$-83.1M
Net Profit
$-78.2M
Gross Margin
N/A
Operating Margin
-612.0%
Net Margin
-576.1%
YoY Growth
2.2%
EPS
$-0.83
Nurix Therapeutics, Inc. Q4 FY2025 Financial Summary
Nurix Therapeutics, Inc. reported revenue of $13.6M (up 2.2% YoY) for Q4 FY2025, with a net profit of $-78.2M (down 33.6% YoY) (-576.1% margin).
Key Financial Metrics
| Total Revenue | $13.6M |
|---|---|
| Net Profit | $-78.2M |
| Gross Margin | N/A |
| Operating Margin | -612.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Nurix Therapeutics, Inc. Q4 FY2025 revenue of $13.6M breaks down across 2 segments, led by Pfizer at $11.9M (87.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pfizer | $11.9M | 87.6% |
| Gilead Agreement | $1.7M | 12.5% |
Nurix Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Nurix Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Pfizer and Gilead Agreement) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Pfizer | $11.9M | — | — | $4.0M |
| Gilead Agreement | $1.7M | — | — | $1.7M |
Nurix Therapeutics, Inc. Annual Revenue by Year
Nurix Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $84.0M).
Nurix Therapeutics, Inc. Quarterly Revenue & Net Profit History
Nurix Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.6M | +2.2% | $-78.2M | -576.1% |
| Q3 FY2025 | $7.9M | -37.3% | $-86.4M | -1094.8% |
| Q2 FY2025 | $44.1M | +264.3% | $-43.5M | -98.7% |
| Q1 FY2025 | $18.5M | +11.3% | $-56.4M | -305.4% |
| Q4 FY2024 | $13.3M | -12.4% | $-58.5M | -440.7% |
| Q3 FY2024 | $12.6M | -31.8% | $-49.0M | -388.9% |
| Q2 FY2024 | $12.1M | -60.6% | $-44.5M | -368.4% |
| Q1 FY2024 | $16.6M | +30.7% | $-41.5M | -250.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.6M | $12.1M | $12.6M | $13.3M | $18.5M | $44.1M | $7.9M | $13.6M |
| YoY Growth | 30.7% | -60.6% | -31.8% | -12.4% | 11.3% | 264.3% | -37.3% | 2.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $312.7M | $511.0M | $513.6M | $669.3M | $615.0M | $591.6M | $522.5M | $688.1M |
| Liabilities | $143.9M | $140.3M | $136.7M | $142.3M | $134.1M | $144.0M | $150.2M | $149.4M |
| Equity | $168.7M | $370.7M | $376.9M | $527.0M | $480.9M | $447.6M | $372.3M | $538.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-42.0M | $-39.7M | $-42.2M | $-48.8M | $-61.1M | $-63.2M | $-57.4M | $-67.8M |